Comparing SEER and NCDB: a case study using colorectal cancer.

Autor: Liu PH; Division of Digestive and Liver Diseases, Department of Medicine, University of Texas Southwestern Medical Center, 5959 Harry Hines Blvd, Suite 520U, Dallas, TX, 75235, USA. stuartliu@gmail.com., Pruitt SL; Peter O'Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX, USA., Singal AG; Division of Digestive and Liver Diseases, Department of Medicine, University of Texas Southwestern Medical Center, 5959 Harry Hines Blvd, Suite 520U, Dallas, TX, 75235, USA., Murphy CC; School of Public Health, University of Texas Health Science Center at Houston, Houston, TX, USA.
Jazyk: angličtina
Zdroj: Cancer causes & control : CCC [Cancer Causes Control] 2024 Nov; Vol. 35 (11), pp. 1477-1485. Date of Electronic Publication: 2024 Aug 06.
DOI: 10.1007/s10552-024-01902-3
Abstrakt: Nationwide datasets are frequently used to examine cancer trends and outcomes in the U.S. Understanding the strengths and limitations of the commonly used Surveillance, Epidemiology, and End Results (SEER) Program and the National Cancer Database (NCDB) is important when designing studies and interpreting results. We used colorectal cancer (CRC) as a case study to compare information available. We identified 575,128 (SEER) and 1,578,046 (NCDB) adults diagnosed with CRC between 2004 and 2021. The distribution of age, tumor location, stage, and treatment did not meaningfully differ between SEER and NCDB. SEER represents racially and ethnically diverse populations, including a higher proportion of Hispanic (11.7% vs 5.8%) and Asian/Pacific Islander (8.6% vs 3.3%) persons. SEER includes more information on area-level characteristics, such as county-level measures of poverty, unemployment, and migration and census tract-level measures of socioeconomic status. Age-adjusted incidence, mortality rates, and cause-specific survival are only available in SEER, facilitating detailed analyses of racial, ethnic, and socioeconomic differences in cancer incidence and mortality. NCDB provides information on tumor characteristics and treatment not available in SEER, including microsatellite instability, KRAS mutation, palliative treatment, unplanned readmissions, and 30-day mortality after surgery, facilitating analyses of treatment effectiveness and outcomes. Five-year overall survival was similar in SEER (55.6%) vs NCDB (57.5%).
Competing Interests: Declarations Competing interests AGS reports consulting for Exact Sciences, Universal Diagnostics, and GRAIL; CCM reports consulting for Freenome and Universal Diagnostics; SLP reports consulting for Pfizer and Gilead; the remaining authors have no conflicts to disclose. Consent to participate The study utilizes two publicly available datasets. We do not have any direct contact with human participants.
(© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.)
Databáze: MEDLINE
Externí odkaz: